Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Mymetics
Mymetics
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
Mymetics-led consortium awarded €8.4m to develop thermo stable and cold-chain independent vaccines
Virosome vaccine technology and HIV vaccine candidate to be used to develop scalable manufacturing process within 3.5 years
Research & Development
Mymetics to advance development of virosome-based malaria vaccine candidate
In partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the NIH
Research & Development
Mymetics’ HIV vaccine candidate to begin study at Texas Biomedical Research Institute
Follows a successfully completed smaller study at the Institute of Laboratory Animal Science (ILAS)
Research & Development
Astellas forms partnership with ClearPath to build vaccine portfolio
In-license vaccine technology for Respiratory Syncytial Virus (RSV) from Mymetics
Research & Development
Mymetics announces change of directors and management
Will explore a number of strategic opportunities for its HIV, RSV and other vaccine candidates
Pharmaceutical
Mymetics makes two appointments
New president and ceo and chairman
Subscribe now